Before and after the spindle assembly checkpoint - An APC/C point of view

The Laboratory of Molecular and Cellular Biology, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institutes of Health, Bethesda, Maryland 20892-0840, USA.
Cell cycle (Georgetown, Tex.) (Impact Factor: 5.01). 10/2006; 5(18):2168-71.
Source: PubMed

ABSTRACT On May 17-21, 2006 the Cold Spring Harbor Laboratory meeting on the cell cycle reunited over 350 researchers to discuss new findings in the cell cycle field. A common thread that connected numerous presentations was the regulation of the anaphase promoting complex/cyclosome (APC/C). This was also the main theme of the lecture given by the keynote speaker, Marc Kirschner (Harvard), who talked about "The unexpected importance of UbcH10 in both the G(1)/S transition and the initiation of anaphase", and it is also the main focus in this summary.

  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: UbcH10 codes for the cancer related E2 Ubiquitin Conjugating Enzyme, an enzymatic molecule with a key role in the ubiquitin-proteasome pathway. Current studies have suggested a critical role of UbcH10 in a variety of malignancies, including human thyroid, breast, ovarian and colorectal carcinomas. The aim of this study has been to extend the analysis of UbcH10 expression to lung cancer. This neoplasia represents one of the leading cause of cancer mortality worldwide, and new tools for an accurate diagnosis/prognosis are needed. METHODS: The expression levels of UbcH10 were analysed in human non-small cell lung carcinoma (NSCLC) by quantitative RT-PCR and tissue microarray immunohistochemistry, and these values were correlated with the clinicopathological features of the patients affected by NSCLC. RESULTS: Our results demonstrate that UbcH10 is overexpressed in NSCLC compared to the normal lung tissue. Moreover, UbcH10 expression is significantly higher in squamous cell and large cell carcinomas than in adenocarcinomas, and directly and inversely correlated with the mutational status of p53 and EGFR, respectively. The suppression of UbcH10 expression by RNAi resulted in a drastic reduction of proliferation and migration abilities of lung carcinoma cell lines. CONCLUSION: These results, taken together, indicate that UbcH10 overexpression has a critical role in lung carcinogenesis, and the evaluation of UbcH10 expression levels may be a new tool for the characterisation of NSCLC.
    European journal of cancer (Oxford, England: 1990) 10/2012; DOI:10.1016/j.ejca.2012.09.033 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: UbcH10 is a component of the Ubiquitin Conjugation Enzymes (Ubc; E2) involved in the ubiquitination cascade controlling the cell cycle progression, whereby ubiquitin, activated by E1, is transferred through E2 to the target protein with the involvement of E3 enzymes. In this work we propose the first three dimensional model of the tetrameric complex formed by the human UbA1 (E1), two ubiquitin molecules and UbcH10 (E2), leading to the transthiolation reaction. The 3D model was built up by using an experimentally guided incremental docking strategy that combined homology modeling, protein-protein docking and refinement by means of molecular dynamics simulations. The structural features of the in silico model allowed us to identify the regions that mediate the recognition between the interacting proteins, revealing the active role of the ubiquitin crosslinked to E1 in the complex formation. Finally, the role of these regions involved in the E1-E2 binding was validated by designing short peptides that specifically interfere with the binding of UbcH10, thus supporting the reliability of the proposed model and representing valuable scaffolds for the design of peptidomimetic compounds that can bind selectively to Ubcs and inhibit the ubiquitylation process in pathological disorders.
    PLoS ONE 11/2014; 9(11):e112082. DOI:10.1371/journal.pone.0112082 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the expression pattern of UbcH10 in non-small cell lung cancer (NSCLC) and its correlations with clinicopathological features and prognostic value in NSCLC patients. The UbcH10 expression in NSCLC tissues, SK-MES-1, and A549 lung cancer cell lines was evaluated, and its correlation with clinicopathological features and prognostic value in NSCLC patients was examined by Kaplan-Meier analysis and Cox regression analysis. The biological effects of UbcH10 on the cell proliferation, cell cycle, and chemosensitivity to gemcitabine or paclitaxel in SK-MES-1 cells were examined upon the UbcH10 silencing. UbcH10 is overexpressed in poorly differentiated NSCLC samples than in well-differentiated ones, and its expression level was significantly higher in squamous cell carcinoma than that in adenocarcinoma. Higher UbcH10 expression was associated with a shorter postoperative survival time of NSCLC patients by Kaplan-Meier method and was found to be an independent risk factor that influences the postoperative survival time of NSCLC patients by Cox regression analysis. UbcH10 mRNA and protein expression were significantly upregulated in SK-MES-1 cells compared with A549 and MRC-5 cells. Suppression of UbcH10 expression in SK-MES-1 cells inhibited cell proliferation and increased chemosensitivity to gemcitabine or paclitaxel concomitant with decreased MDR1 gene expression. UbcH10 may play an important role in NSCLC carcinogenesis, and silencing UbcH10 may represent a potential therapeutic strategy for NSCLC.
    Journal of Cancer Research and Clinical Oncology 07/2012; 138(11):1951-61. DOI:10.1007/s00432-012-1275-2 · 3.01 Impact Factor